Evidence map›Paper›PMID 40532856›Full record

ArticleThe Journal of infection2025

Blastemia portrays a poor prognosis in acute leukemia patients with invasive pulmonary aspergillosis.

Sung-Yeon Cho, Sebastian Wurster, Ying Jiang, Alexandre Bazinet, Yang Hui, Russel E Lewis, Takahiro Matsuo, Nathaniel Albert, Guillermo Garcia-Manero, Dimitrios P Kontoyiannis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sung-Yeon ChoDepartment of Infectious Diseases, University of Texas, MD Anderson Cancer Center, TX, United States; Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea.
Sebastian WursterDepartment of Infectious Diseases, University of Texas, MD Anderson Cancer Center, TX, United States.
Ying JiangDepartment of Infectious Diseases, University of Texas, MD Anderson Cancer Center, TX, United States.
Alexandre BazinetDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, TX, United States.
Yang HuiDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, TX, United States.
Russel E LewisInfectious Diseases in the Department of Molecular Medicine, University of Padua, Italy.
Takahiro MatsuoDepartment of Infectious Diseases, University of Texas, MD Anderson Cancer Center, TX, United States.
Nathaniel AlbertDepartment of Infectious Diseases, University of Texas, MD Anderson Cancer Center, TX, United States.
Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, TX, United States.
Dimitrios P KontoyiannisDepartment of Infectious Diseases, University of Texas, MD Anderson Cancer Center, TX, United States. Electronic address: dkontoyi@mdanderson.org.

Funding

Development of an acute myeloid leukemia murine model of invasive pulmonary aspergillosis to gain insights into the role of leukemia and its treatments in the pathobiology of aspergillosisR03AI166285 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONTOYIANNIS, DIMITRIOS P · 2022 to 2023
$162k
NIAID NIH HHS R03 AI166285
6 · The paper itself

Abstract

objectivesSevere and prolonged neutropenia is associated with poor outcomes of invasive pulmonary aspergillosis (IPA) in leukemia patients. Given the high frequency of IPA in patients with relapsed/refractory leukemia, we studied the association of peripheral blood blast burden (blastemia), IPA outcomes, and antifungal immune failure, even without neutropenia.

methodsWe retrospectively reviewed adult patients with acute leukemia (AL) or myelodysplastic syndrome and culture-positive proven/probable IPA (2011-2022). Blast and neutropenia indices were calculated and incorporated into multi-variable prognostic models. The impact of blasts on immune cell-mediated fungal clearance was studied in vitro.

resultsAmong 74 patients, 69% had neutropenia and 57% had blastemia at IPA diagnosis. Blast index ≥90 at IPA diagnosis and ≥3 lines of prior chemotherapies were independent predictors of 42-day mortality and early antifungal treatment failure. Leukemic blasts had minimal immune activity against Aspergillus fumigatus and impaired fungal inhibition by peripheral blood mononuclear cells.

conclusionBlastemia is common in contemporary leukemia patients with IPA and is a significant risk factor for poor IPA outcomes, possibly due to interference with fungal clearance by immune cells. Therefore, blastemia should be considered as a risk stratification parameter in future mycology trials and as an experimental variable in preclinical IPA models.

Indexed as

Invasive Pulmonary AspergillosisLeukemiaAdultAgedAged, 80 and overAntifungal AgentsAspergillus fumigatusFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesNeutropeniaPrognosisRetrospective StudiesRisk FactorsAntifungal AgentsAcute leukemiaBlastemiaInvasive pulmonary aspergillosis

Identifiers

PMID40532856
PMCPMC12416181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.